Morimasa Yagisawa, visiting professor at Kitasato University, Omura Satoshi Memorial Institute in Tokyo, went on the record that the World Health Organization, drug regulators, and health policy makers shouldn’t ignore anymore the growing data that ivermectin can be an effective and safe adjuvant treatment for COVID-19. Citing accumulating clinical trials data, including many doctor-initiated studies, the professor cited in a virtual interview that 105 studies of ivermectin associated with the coronavirus across 32 nations have been registered, of which 24 have been completed and published. The professor declared that “ivermectin is almighty for prophylaxis, for treatment of early and late stage, and also for long COVID-19 (or) post-acute sequelae (of SARS-CoV-2).”
Yagisawa is one of four authors that produced a report titled “Global trends in clinical studies of ivermectin in COVID-19” published in March in the “Japanese Journal of Antibiotics.” He was joined in that report by Satoshi Omura, the biochemist, along with William Campbell who was awarded the 2015 Nobel Prize in Physiology or Medicine associated with the discovery of avermectin, the derivative of which ivermectin is made.
“by the 27th of February, the results of 42 clinical trials, including approximately 15,000 patients (both registered and unregistered studies) have been subjected to a meta-analysis after exclusion of biasing factors. It was found that 83% showed improvements with early treatment, 51% improved during late-stage treatment, and there was an 89% prevention of onset rate noted. This confirms the usefulness of ivermectin. Since it is a meta-analysis based on 42 test results, it is estimated that the probability of this comprehensive judgment being a mistake is as low as 1 in 4 trillion. In addition, two separate meta-analyses also showed the 46 (46) THE JAPANESE JOURNAL OF ANTIBIOTICS 74―1 Mar. 2021 usefulness of ivermectin and their conclusions were presented to the WHO and the US FDA with a request for an expansion of the indication of ivermectin in the treatment of COVID-19.”
Considered Modes of Action
During this interview, as reported in the ABS-CBN, the professor discussed, “the probable modes of action against SARS-CoV-2,” include the drug’s ability to 1) inhibit the entry of the virus into the human cell and/or 2) prevent protein processing from occurring if the virus in fact entered the human cell. A Filipino news organization called ABS-CBN reported on this material declaration and recently shared a screenshot from Professor Yagisawa’s presentation during the virtual interview on May 6, 2021.
Kitasato University Clinical Trial
TrialSite reported that Kitasato University commenced an ivermectin-based clinical trial, which apparently has gone slowly due to patient enrollment issues. TrialSite reported that the university started discussions with Merck back in May 2020. Of course, TrialSite suggested nefarious reasons for Merck’s very public bashing of its own version of the drug in connection to COVID-19—that point of view can be reviewed here.
By September 2020, the university declared they would be conducting the study.
Call to Action: Check out the report titled “Global trends in clinical studies of ivermectin in COVID-19” published in March in the “Japanese Journal of Antibiotics.”